

Maria Pia amato

List of Publications by Citations

Source: <https://exaly.com/author-pdf/8772511/maria-pia-amato-publications-by-citations.pdf>
Version: 2024-04-09

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.
The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

281 papers	14,775 citations	67 h-index	111 g-index
294 ext. papers	17,228 ext. citations	5.3 avg, IF	6.09 L-index

#	Paper	IF	Citations
281	International Pediatric Multiple Sclerosis Study Group criteria for pediatric multiple sclerosis and immune-mediated central nervous system demyelinating disorders: revisions to the 2007 definitions. <i>Multiple Sclerosis Journal</i> , 2013 , 19, 1261-7	5	646
280	Recommendations for a Brief International Cognitive Assessment for Multiple Sclerosis (BICAMS). <i>Multiple Sclerosis Journal</i> , 2012 , 18, 891-8	5	493
279	Cognitive dysfunction in early-onset multiple sclerosis: a reappraisal after 10 years. <i>Archives of Neurology</i> , 2001 , 58, 1602-6		489
278	Multiple sclerosis-related cognitive changes: a review of cross-sectional and longitudinal studies. <i>Journal of the Neurological Sciences</i> , 2006 , 245, 41-6	3.2	404
277	Clinical and imaging assessment of cognitive dysfunction in multiple sclerosis. <i>Lancet Neurology</i> , 2015 , 14, 302-17	24.1	322
276	ECTRIMS/EAN Guideline on the pharmacological treatment of people with multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2018 , 24, 96-120	5	286
275	Cognitive impairment in early-onset multiple sclerosis. Pattern, predictors, and impact on everyday life in a 4-year follow-up. <i>Archives of Neurology</i> , 1995 , 52, 168-72		284
274	The RaoB Brief Repeatable Battery and Stroop Test: normative values with age, education and gender corrections in an Italian population. <i>Multiple Sclerosis Journal</i> , 2006 , 12, 787-93	5	273
273	Neocortical volume decrease in relapsing-remitting MS patients with mild cognitive impairment. <i>Neurology</i> , 2004 , 63, 89-93	6.5	253
272	The prevalence of pain in multiple sclerosis: a multicenter cross-sectional study. <i>Neurology</i> , 2004 , 63, 919-21	6.5	221
271	Cognitive and psychosocial features of childhood and juvenile MS. <i>Neurology</i> , 2008 , 70, 1891-7	6.5	209
270	Brief International Cognitive Assessment for MS (BICAMS): international standards for validation. <i>BMC Neurology</i> , 2012 , 12, 55	3.1	208
269	New natural history of interferon-beta-treated relapsing multiple sclerosis. <i>Annals of Neurology</i> , 2007 , 61, 300-6	9.4	208
268	Radiologically isolated syndrome: 5-year risk for an initial clinical event. <i>PLoS ONE</i> , 2014 , 9, e90509	3.7	190
267	Comparison of fingolimod with interferon beta-1a in relapsing-remitting multiple sclerosis: a randomised extension of the TRANSFORMS study. <i>Lancet Neurology</i> , 2011 , 10, 520-9	24.1	178
266	Association of neocortical volume changes with cognitive deterioration in relapsing-remitting multiple sclerosis. <i>Archives of Neurology</i> , 2007 , 64, 1157-61		174
265	Defining secondary progressive multiple sclerosis. <i>Brain</i> , 2016 , 139, 2395-405	11.2	172

264	Cognitive and psychosocial features in childhood and juvenile MS: two-year follow-up. <i>Neurology</i> , 2010 , 75, 1134-40	6.5	170
263	Treatment of cognitive impairment in multiple sclerosis: position paper. <i>Journal of Neurology</i> , 2013 , 260, 1452-68	5.5	161
262	Autologous hematopoietic stem cell transplantation in multiple sclerosis: a phase II trial. <i>Neurology</i> , 2015 , 84, 981-8	6.5	155
261	Consensus statement: evaluation of new and existing therapeutics for pediatric multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2012 , 18, 116-27	5	149
260	Cognitive impairment and its relation with disease measures in mildly disabled patients with relapsing-remitting multiple sclerosis: baseline results from the Cognitive Impairment in Multiple Sclerosis (COGIMUS) study. <i>Multiple Sclerosis Journal</i> , 2009 , 15, 779-88	5	141
259	Geographical variations in sex ratio trends over time in multiple sclerosis. <i>PLoS ONE</i> , 2012 , 7, e48078	3.7	139
258	Age and disability drive cognitive impairment in multiple sclerosis across disease subtypes. <i>Multiple Sclerosis Journal</i> , 2017 , 23, 1258-1267	5	136
257	Relevance of cognitive deterioration in early relapsing-remitting MS: a 3-year follow-up study. <i>Multiple Sclerosis Journal</i> , 2010 , 16, 1474-82	5	136
256	Association of MRI metrics and cognitive impairment in radiologically isolated syndromes. <i>Neurology</i> , 2012 , 78, 309-14	6.5	129
255	Establishing pathological cut-offs of brain atrophy rates in multiple sclerosis. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2016 , 87, 93-9	5.5	125
254	Benign multiple sclerosis: cognitive, psychological and social aspects in a clinical cohort. <i>Journal of Neurology</i> , 2006 , 253, 1054-9	5.5	123
253	Pregnancy and fetal outcomes after interferon- β exposure in multiple sclerosis. <i>Neurology</i> , 2010 , 75, 1794-802	6.5	121
252	Cognitive changes in multiple sclerosis. <i>Expert Review of Neurotherapeutics</i> , 2008 , 8, 1585-96	4.3	119
251	Cognitive impairment predicts conversion to multiple sclerosis in clinically isolated syndromes. <i>Multiple Sclerosis Journal</i> , 2010 , 16, 62-7	5	118
250	Breastfeeding is not related to postpartum relapses in multiple sclerosis. <i>Neurology</i> , 2011 , 77, 145-50	6.5	116
249	Cognitive impairment in early stages of multiple sclerosis. <i>Neurological Sciences</i> , 2010 , 31, S211-4	3.5	113
248	Real-life impact of early interferon beta therapy in relapsing multiple sclerosis. <i>Annals of Neurology</i> , 2009 , 66, 513-20	9.4	109
247	Predictors and dynamics of postpartum relapses in women with multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2014 , 20, 739-46	5	104

246	Can the Expanded Disability Status Scale be assessed by telephone?. <i>Multiple Sclerosis Journal</i> , 2003 , 9, 154-9	5	103
245	Prevalence of neuromyelitis optica spectrum disorder and phenotype distribution. <i>Journal of Neurology</i> , 2009 , 256, 1891-8	5.5	101
244	A prospective study on the natural history of multiple sclerosis: clues to the conduct and interpretation of clinical trials. <i>Journal of the Neurological Sciences</i> , 1999 , 168, 96-106	3.2	98
243	ECTRIMS/EAN guideline on the pharmacological treatment of people with multiple sclerosis. <i>European Journal of Neurology</i> , 2018 , 25, 215-237	6	96
242	Primary Progressive Multiple Sclerosis Evolving From Radiologically Isolated Syndrome. <i>Annals of Neurology</i> , 2016 , 79, 288-94	9.4	96
241	Sex as a determinant of relapse incidence and progressive course of multiple sclerosis. <i>Brain</i> , 2013 , 136, 3609-17	11.2	96
240	Autologous haematopoietic stem cell transplantation with an intermediate intensity conditioning regimen in multiple sclerosis: the Italian multi-centre experience. <i>Multiple Sclerosis Journal</i> , 2012 , 18, 835-42	5	95
239	Cognitive assessment and quantitative magnetic resonance metrics can help to identify benign multiple sclerosis. <i>Neurology</i> , 2008 , 71, 632-8	6.5	95
238	Cognitive reserve and cortical atrophy in multiple sclerosis: a longitudinal study. <i>Neurology</i> , 2013 , 80, 1728-33	6.5	93
237	Disease-modifying drugs in childhood-juvenile multiple sclerosis: results of an Italian co-operative study. <i>Multiple Sclerosis Journal</i> , 2005 , 11, 420-4	5	90
236	Coping strategies, psychological variables and their relationship with quality of life in multiple sclerosis. <i>Neurological Sciences</i> , 2009 , 30, 15-20	3.5	88
235	Comparison of switch to fingolimod or interferon beta/glatiramer acetate in active multiple sclerosis. <i>JAMA Neurology</i> , 2015 , 72, 405-13	17.2	83
234	Cognitive impairment in multiple sclerosis: clinical management, MRI, and therapeutic avenues. <i>Lancet Neurology</i> , 2020 , 19, 860-871	24.1	83
233	Computer-assisted rehabilitation of attention in patients with multiple sclerosis: results of a randomized, double-blind trial. <i>Multiple Sclerosis Journal</i> , 2014 , 20, 91-8	5	81
232	Pediatric multiple sclerosis: Clinical features and outcome. <i>Neurology</i> , 2016 , 87, S74-81	6.5	80
231	Male Sex Is Independently Associated with Faster Disability Accumulation in Relapse-Onset MS but Not in Primary Progressive MS. <i>PLoS ONE</i> , 2015 , 10, e0122686	3.7	80
230	Neuropsychological features in childhood and juvenile multiple sclerosis: five-year follow-up. <i>Neurology</i> , 2014 , 83, 1432-8	6.5	78
229	The Brief International Cognitive Assessment for Multiple Sclerosis (BICAMS): normative values with gender, age and education corrections in the Italian population. <i>BMC Neurology</i> , 2014 , 14, 171	3.1	78

228	Long-term adherence to interferon beta therapy in relapsing-remitting multiple sclerosis. <i>European Neurology</i> , 2008 , 59, 131-5	2.1	78
227	Effects of immunomodulatory treatment with subcutaneous interferon beta-1a on cognitive decline in mildly disabled patients with relapsing-remitting multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2010 , 16, 68-77	5	75
226	Spinal cord involvement in multiple sclerosis and neuromyelitis optica spectrum disorders. <i>Lancet Neurology</i> , 2019 , 18, 185-197	24.1	74
225	Evolving expectations around early management of multiple sclerosis. <i>Therapeutic Advances in Neurological Disorders</i> , 2010 , 3, 351-67	6.6	74
224	Neuropsychological and MRI measures predict short-term evolution in benign multiple sclerosis. <i>Neurology</i> , 2009 , 73, 498-503	6.5	74
223	The costs of multiple sclerosis: a cross-sectional, multicenter cost-of-illness study in Italy. <i>Journal of Neurology</i> , 2002 , 249, 152-63	5.5	74
222	Pregnancy and fetal outcomes after Glatiramer Acetate exposure in patients with multiple sclerosis: a prospective observational multicentric study. <i>BMC Neurology</i> , 2012 , 12, 124	3.1	72
221	A prospective, randomized, controlled trial of autologous haematopoietic stem cell transplantation for aggressive multiple sclerosis: a position paper. <i>Multiple Sclerosis Journal</i> , 2012 , 18, 825-34	5	70
220	The management of multiple sclerosis in children: a European view. <i>Multiple Sclerosis Journal</i> , 2010 , 16, 1258-67	5	69
219	Coping strategies, cognitive impairment, psychological variables and their relationship with quality of life in multiple sclerosis. <i>Neurological Sciences</i> , 2010 , 31, S227-30	3.5	69
218	Differences in mesenchymal stem cell cytokine profiles between MS patients and healthy donors: implication for assessment of disease activity and treatment. <i>Journal of Neuroimmunology</i> , 2008 , 199, 142-50	3.5	69
217	Impact of natalizumab on cognitive performances and fatigue in relapsing multiple sclerosis: a prospective, open-label, two years observational study. <i>PLoS ONE</i> , 2012 , 7, e35843	3.7	68
216	Brain damage as detected by magnetization transfer imaging is less pronounced in benign than in early relapsing multiple sclerosis. <i>Brain</i> , 2006 , 129, 2008-16	11.2	68
215	Caregiver quality of life in multiple sclerosis: a multicentre Italian study. <i>Multiple Sclerosis Journal</i> , 2007 , 13, 412-9	5	68
214	Cortical lesions in radiologically isolated syndrome. <i>Neurology</i> , 2011 , 77, 1896-9	6.5	67
213	Epidural analgesia and cesarean delivery in multiple sclerosis post-partum relapses: the Italian cohort study. <i>BMC Neurology</i> , 2012 , 12, 165	3.1	66
212	Fatigue and its relationships with cognitive functioning and depression in paediatric multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2012 , 18, 329-34	5	65
211	Fingolimod versus interferon beta/glatiramer acetate after natalizumab suspension in multiple sclerosis. <i>Brain</i> , 2015 , 138, 3275-86	11.2	63

210	Efficacy and safety of cannabinoid oromucosal spray for multiple sclerosis spasticity. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2016 , 87, 944-51	5.5	63
209	Towards personalized therapy for multiple sclerosis: prediction of individual treatment response. <i>Brain</i> , 2017 , 140, 2426-2443	11.2	62
208	Relevance of brain lesion location to cognition in relapsing multiple sclerosis. <i>PLoS ONE</i> , 2012 , 7, e44826	3.7	61
207	Pediatric multiple sclerosis: Cognition and mood. <i>Neurology</i> , 2016 , 87, S82-7	6.5	60
206	Altered cerebellar functional connectivity mediates potential adaptive plasticity in patients with multiple sclerosis. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2004 , 75, 840-6	5.5	60
205	Acute myeloid leukemia in Italian patients with multiple sclerosis treated with mitoxantrone. <i>Neurology</i> , 2011 , 77, 1887-95	6.5	59
204	Fertility, pregnancy and childbirth in patients with multiple sclerosis: impact of disease-modifying drugs. <i>CNS Drugs</i> , 2015 , 29, 207-20	6.7	58
203	Environmental modifiable risk factors for multiple sclerosis: Report from the 2016 ECTRIMS focused workshop. <i>Multiple Sclerosis Journal</i> , 2018 , 24, 590-603	5	58
202	Long-term results of immunomodulatory treatment in children and adolescents with multiple sclerosis: the Italian experience. <i>Neurological Sciences</i> , 2009 , 30, 193-9	3.5	58
201	Frequency and risk factors of mitoxantrone-induced amenorrhea in multiple sclerosis: the FEMIMS study. <i>Multiple Sclerosis Journal</i> , 2008 , 14, 1225-33	5	58
200	Seasonal variation of relapse rate in multiple sclerosis is latitude dependent. <i>Annals of Neurology</i> , 2014 , 76, 880-90	9.4	57
199	Pediatric multiple sclerosis: Conventional first-line treatment and general management. <i>Neurology</i> , 2016 , 87, S97-S102	6.5	56
198	Improving the characterization of radiologically isolated syndrome suggestive of multiple sclerosis. <i>PLoS ONE</i> , 2011 , 6, e19452	3.7	55
197	Pregnancy decision-making in women with multiple sclerosis treated with natalizumab: I: Fetal risks. <i>Neurology</i> , 2018 , 90, e823-e831	6.5	54
196	Supportive strategies to improve adherence to IFN β 1b in multiple sclerosis--results of the Plus observational cohort study. <i>Journal of the Neurological Sciences</i> , 2011 , 307, 120-6	3.2	54
195	Immunomodulatory treatment of early onset multiple sclerosis: results of an Italian Co-operative Study. <i>Neurological Sciences</i> , 2005 , 26 Suppl 4, S183-6	3.5	52
194	Brain metabolic changes suggestive of axonal damage in radiologically isolated syndrome. <i>Neurology</i> , 2013 , 80, 2090-4	6.5	51
193	Immunoproteasome LMP2 60HH variant alters MBP epitope generation and reduces the risk to develop multiple sclerosis in Italian female population. <i>PLoS ONE</i> , 2010 , 5, e9287	3.7	51

192	Risk of relapse phenotype recurrence in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2014 , 20, 1511-22	5	49
191	Treatment of early-onset multiple sclerosis with intramuscular interferonbeta-1a: long-term results. <i>Neurological Sciences</i> , 2007 , 28, 127-32	3.5	49
190	Pregnancy decision-making in women with multiple sclerosis treated with natalizumab: II: Maternal risks. <i>Neurology</i> , 2018 , 90, e832-e839	6.5	48
189	Postpartum relapses increase the risk of disability progression in multiple sclerosis: the role of disease modifying drugs. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2014 , 85, 845-50	5.5	48
188	Early prediction of the long term evolution of multiple sclerosis: the Bayesian Risk Estimate for Multiple Sclerosis (BREMS) score. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2007 , 78, 757-9	5.5	47
187	Quantification of impairment in MS: discussion of the scales in use. <i>Multiple Sclerosis Journal</i> , 1999 , 5, 216-9	5	46
186	Withdrawal of fingolimod treatment for relapsing-remitting multiple sclerosis: report of six cases. <i>Multiple Sclerosis Journal</i> , 2012 , 18, 1636-9	5	44
185	The brief neuropsychological battery for children: a screening tool for cognitive impairment in childhood and juvenile multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2009 , 15, 620-6	5	44
184	Higher latitude is significantly associated with an earlier age of disease onset in multiple sclerosis. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2016 , 87, 1343-1349	5.5	44
183	Highly active immunomodulatory therapy ameliorates accumulation of disability in moderately advanced and advanced multiple sclerosis. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2017 , 88, 196-203	5.5	43
182	Radiologically isolated syndrome or subclinical multiple sclerosis: MAGNIMS consensus recommendations. <i>Multiple Sclerosis Journal</i> , 2018 , 24, 214-221	5	43
181	Safety of the first dose of fingolimod for multiple sclerosis: results of an open-label clinical trial. <i>BMC Neurology</i> , 2014 , 14, 65	3.1	43
180	Reliability, practice effects, and change indices for RaoB Brief Repeatable Battery. <i>Multiple Sclerosis Journal</i> , 2010 , 16, 611-7	5	43
179	Subcutaneous interferon E1a may protect against cognitive impairment in patients with relapsing-remitting multiple sclerosis: 5-year follow-up of the COGIMUS study. <i>PLoS ONE</i> , 2013 , 8, e74111	3.7	42
178	Clinical outcome measures in multiple sclerosis. <i>Journal of the Neurological Sciences</i> , 2007 , 259, 118-22	3.2	42
177	Influence of apolipoprotein E epsilon4 genotype on brain tissue integrity in relapsing-remitting multiple sclerosis. <i>Archives of Neurology</i> , 2004 , 61, 536-40		42
176	The Italian multiple sclerosis register. <i>Neurological Sciences</i> , 2019 , 40, 155-165	3.5	42
175	Are there protective treatments for cognitive decline in MS?. <i>Journal of the Neurological Sciences</i> , 2006 , 245, 183-6	3.2	41

174	Posterior brain damage and cognitive impairment in pediatric multiple sclerosis. <i>Neurology</i> , 2014 , 82, 1314-21	6.5	40
173	Impact of cognitive impairment on coping strategies in multiple sclerosis. <i>Clinical Neurology and Neurosurgery</i> , 2010 , 112, 127-30	2	40
172	Anxiety state affects information processing speed in patients with multiple sclerosis. <i>Neurological Sciences</i> , 2014 , 35, 559-63	3.5	39
171	Prevalence of patient-reported dysphagia in multiple sclerosis patients: an Italian multicenter study (using the DYMUS questionnaire). <i>Journal of the Neurological Sciences</i> , 2013 , 331, 94-7	3.2	39
170	Natalizumab may reduce cognitive changes and brain atrophy rate in relapsing-remitting multiple sclerosis--a prospective, non-randomized pilot study. <i>European Journal of Neurology</i> , 2013 , 20, 986-90	6	39
169	Quality of life, depression and fatigue in mildly disabled patients with relapsing-remitting multiple sclerosis receiving subcutaneous interferon beta-1a: 3-year results from the COGIMUS (COGNitive Impairment in Multiple Sclerosis) study. <i>Multiple Sclerosis Journal</i> , 2011 , 17, 991-1001	5	39
168	Management options in multiple sclerosis-associated fatigue. <i>Expert Opinion on Pharmacotherapy</i> , 2012 , 13, 207-16	4	38
167	Dysregulation of sphingosine 1 phosphate receptor-1 (S1P1) signaling and regulatory lymphocyte-dependent immunosuppression in a model of post-fingolimod MS rebound. <i>Brain, Behavior, and Immunity</i> , 2015 , 50, 78-86	16.6	37
166	Relevance of hypointense brain MRI lesions for long-term worsening of clinical disability in relapsing multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2014 , 20, 214-9	5	37
165	Immunomodulatory therapies delay disease progression in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2016 , 22, 1732-1740	5	36
164	Predictors of disability worsening in clinically isolated syndrome. <i>Annals of Clinical and Translational Neurology</i> , 2015 , 2, 479-91	5.3	36
163	Psychosocial issue in children and adolescents with multiple sclerosis. <i>Neurological Sciences</i> , 2010 , 31, 467-70	3.5	36
162	Efficacy of fingolimod and interferon beta-1b on cognitive, MRI, and clinical outcomes in relapsing-remitting multiple sclerosis: an 18-month, open-label, rater-blinded, randomised, multicentre study (the GOLDEN study). <i>Journal of Neurology</i> , 2017 , 264, 2436-2449	5.5	35
161	Radiologically Isolated Syndrome: 10-Year Risk Estimate of a Clinical Event. <i>Annals of Neurology</i> , 2020 , 88, 407-417	9.4	35
160	European validation of a standardized clinical description of multiple sclerosis. <i>Journal of Neurology</i> , 2004 , 251, 1472-80	5.5	35
159	Intranetwork and internetwork functional connectivity abnormalities in pediatric multiple sclerosis. <i>Human Brain Mapping</i> , 2014 , 35, 4180-92	5.9	34
158	Recommendations for the management of urinary disorders in multiple sclerosis: a consensus of the Italian Multiple Sclerosis Study Group. <i>Neurological Sciences</i> , 2011 , 32, 1223-31	3.5	33
157	Changes in neuropsychological test performance over the workday in multiple sclerosis. <i>Clinical Neuropsychologist</i> , 2003 , 17, 551-60	4.4	32

156	A short version of Rao's Brief Repeatable Battery as a screening tool for cognitive impairment in multiple sclerosis. <i>Clinical Neuropsychologist</i> , 2009 , 23, 268-75	4.4	31
155	The effect of oral immunomodulatory therapy on treatment uptake and persistence in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2016 , 22, 520-32	5	30
154	Appraisal of brain connectivity in radiologically isolated syndrome by modeling imaging measures. <i>Journal of Neuroscience</i> , 2015 , 35, 550-8	6.6	30
153	Comparative effectiveness of glatiramer acetate and interferon beta formulations in relapsing-remitting multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2015 , 21, 1159-71	5	30
152	Improving compliance with interferon-beta therapy in patients with multiple sclerosis. <i>CNS Drugs</i> , 2009 , 23, 453-62	6.7	30
151	Absence of cerebrospinal fluid oligoclonal bands is associated with delayed disability progression in relapsing-remitting MS patients treated with interferon-beta. <i>Journal of the Neurological Sciences</i> , 2006 , 244, 97-102	3.2	30
150	Cerebrospinal fluid findings in Devic's neuromyelitis optica. <i>Neurological Sciences</i> , 2004 , 25 Suppl 4, S368-70	3.5	30
149	Multiple sclerosis in Italy: cost-of-illness study. <i>Neurological Sciences</i> , 2011 , 32, 787-94	3.5	29
148	Response to interferon-beta therapy in relapsing-remitting multiple sclerosis: a comparison of different clinical criteria. <i>Multiple Sclerosis Journal</i> , 2006 , 12, 281-6	5	29
147	Guidelines on the clinical use for the detection of neutralizing antibodies (NAbs) to IFN beta in multiple sclerosis therapy: report from the Italian Multiple Sclerosis Study group. <i>Neurological Sciences</i> , 2014 , 35, 307-16	3.5	28
146	The coexistence of well- and ill-being in persons with multiple sclerosis, their caregivers and health professionals. <i>Journal of the Neurological Sciences</i> , 2014 , 337, 67-73	3.2	28
145	A comparison of the brief international cognitive assessment for multiple sclerosis and the brief repeatable battery in multiple sclerosis patients. <i>BMC Neurology</i> , 2015 , 15, 204	3.1	28
144	Subclinical MSP follow-up of four cases. <i>European Journal of Neurology</i> , 2008 , 15, 858-61	6	28
143	Neocortical volume decrease in relapsing-remitting multiple sclerosis with mild cognitive impairment. <i>Journal of the Neurological Sciences</i> , 2006 , 245, 195-9	3.2	28
142	Safety and tolerability of cyclophosphamide pulses in multiple sclerosis: a prospective study in a clinical cohort. <i>Multiple Sclerosis Journal</i> , 2003 , 9, 446-50	5	28
141	Illness Perception and Well-Being Among Persons with Multiple Sclerosis and Their Caregivers. <i>Journal of Clinical Psychology in Medical Settings</i> , 2016 , 23, 33-52	2	27
140	Clinical outcome measures for progressive MS trials. <i>Multiple Sclerosis Journal</i> , 2017 , 23, 1627-1635	5	27
139	Prognostic indicators in pediatric clinically isolated syndrome. <i>Annals of Neurology</i> , 2017 , 81, 729-739	9.4	26

138	The contribution of cerebrospinal fluid oligoclonal bands to the early diagnosis of multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2009 , 15, 472-8	5	26
137	The Italian Multiple Sclerosis Database Network (MSDN): the risk of worsening according to IFNbeta exposure in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2006 , 12, 578-85	5	26
136	Three years of experience: the Italian registry and safety data update. <i>Neurological Sciences</i> , 2011 , 31 Suppl 3, 295-7	3.5	25
135	Aging with multiple sclerosis: prevalence and profile of cognitive impairment. <i>Neurological Sciences</i> , 2019 , 40, 1651-1657	3.5	24
134	Patients with paediatric-onset multiple sclerosis are at higher risk of cognitive impairment in adulthood: An Italian collaborative study. <i>Multiple Sclerosis Journal</i> , 2018 , 24, 1234-1242	5	24
133	Cortical functional reorganization and its relationship with brain structural damage in patients with benign multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2010 , 16, 1326-34	5	24
132	Motor evoked potentials in multiple sclerosis patients without walking limitation: amplitude vs. conduction time abnormalities. <i>Journal of Neurology</i> , 2007 , 254, 220-7	5.5	24
131	Autologous hematopoietic stem cell transplantation for very active relapsing-remitting multiple sclerosis: report of two cases. <i>Multiple Sclerosis Journal</i> , 2007 , 13, 676-8	5	24
130	Rebound after Fingolimod suspension in a pediatric-onset multiple sclerosis patient. <i>Journal of Neurology</i> , 2013 , 260, 1675-7	5.5	23
129	A double blind, placebo-controlled, phase II, add-on study of cyclophosphamide (CTX) for 24 months in patients affected by multiple sclerosis on a background therapy with interferon-beta study denomination: CYCLIN. <i>Journal of the Neurological Sciences</i> , 2004 , 223, 69-71	3.2	23
128	Identifying the Distinct Cognitive Phenotypes in Multiple Sclerosis. <i>JAMA Neurology</i> , 2021 , 78, 414-425	17.2	23
127	Contribution of different relapse phenotypes to disability in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2017 , 23, 266-276	5	22
126	Long-term assessment of no evidence of disease activity in relapsing-remitting MS. <i>Neurology</i> , 2015 , 85, 1722-3	6.5	22
125	Paternal therapy with disease modifying drugs in multiple sclerosis and pregnancy outcomes: a prospective observational multicentric study. <i>BMC Neurology</i> , 2014 , 14, 114	3.1	22
124	The RaoB Brief Repeatable Battery version B: normative values with age, education and gender corrections in an Italian population. <i>Neurological Sciences</i> , 2014 , 35, 79-82	3.5	22
123	Persistence on therapy and propensity matched outcome comparison of two subcutaneous interferon beta 1a dosages for multiple sclerosis. <i>PLoS ONE</i> , 2013 , 8, e63480	3.7	22
122	Post-marketing of disease modifying drugs in multiple sclerosis: an exploratory analysis of gender effect in interferon beta treatment. <i>Journal of the Neurological Sciences</i> , 2009 , 286, 109-13	3.2	22
121	Intravenous mitoxantrone and cyclophosphamide as second-line therapy in multiple sclerosis: an open-label comparative study of efficacy and safety. <i>Journal of the Neurological Sciences</i> , 2008 , 266, 25-30	3.2	22

120	Cognitive impairment in paediatric multiple sclerosis patients is not related to cortical lesions. <i>Multiple Sclerosis Journal</i> , 2015 , 21, 956-9	5	21
119	Regional hippocampal involvement and cognitive impairment in pediatric multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2016 , 22, 628-40	5	20
118	Increased CD8+ T cell responses to apoptotic T cell-associated antigens in multiple sclerosis. <i>Journal of Neuroinflammation</i> , 2013 , 10, 94	10.1	20
117	The direct cost of patients with multiple sclerosis: a survey from Italian MS centres. <i>Neurological Sciences</i> , 2011 , 32, 1035-41	3.5	20
116	Cognitive impairment in pediatric multiple sclerosis. <i>Neurological Sciences</i> , 2010 , 31, S215-8	3.5	20
115	Disease-modifying drugs can reduce disability progression in relapsing multiple sclerosis. <i>Brain</i> , 2020 , 143, 3013-3024	11.2	20
114	Long-term follow-up of pediatric MS patients starting treatment with injectable first-line agents: A multicentre, Italian, retrospective, observational study. <i>Multiple Sclerosis Journal</i> , 2019 , 25, 399-407	5	20
113	The cognitive reserve theory in the setting of pediatric-onset multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2016 , 22, 1741-1749	5	19
112	Management of pregnancy-related issues in multiple sclerosis patients: the need for an interdisciplinary approach. <i>Neurological Sciences</i> , 2017 , 38, 1849-1858	3.5	19
111	Beyond Disease: Happiness, Goals, and Meanings among Persons with Multiple Sclerosis and Their Caregivers. <i>Frontiers in Psychology</i> , 2017 , 8, 2216	3.4	19
110	Sex effects across the lifespan in women with multiple sclerosis. <i>Therapeutic Advances in Neurological Disorders</i> , 2020 , 13, 1756286420936166	6.6	19
109	Long-term disability trajectories in primary progressive MS patients: A latent class growth analysis. <i>Multiple Sclerosis Journal</i> , 2018 , 24, 642-652	5	18
108	No evidence for an effect on brain atrophy rate of atorvastatin add-on to interferon β therapy in relapsing-remitting multiple sclerosis (the ARIANNA study). <i>Multiple Sclerosis Journal</i> , 2016 , 22, 1163-73	5	18
107	A 10-year follow-up of the European multicenter trial of interferon β 1b in secondary-progressive multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2016 , 22, 533-43	5	18
106	No association between chronic cerebrospinal venous insufficiency and pediatric-onset multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2012 , 18, 1791-6	5	18
105	Truly benign multiple sclerosis is rare: let's stop fooling ourselves--yes. <i>Multiple Sclerosis Journal</i> , 2012 , 18, 13-4	5	18
104	Impact of COVID-19 on multiple sclerosis care and management: Results from the European Committee for Treatment and Research in Multiple Sclerosis survey. <i>Multiple Sclerosis Journal</i> , 2021 , 27, 13524585211005339	5	18
103	Cognitive assessment in multiple sclerosis-an Italian consensus. <i>Neurological Sciences</i> , 2018 , 39, 1317-1334	3.5	18

102	Identifying risk factors for cognitive issues in multiple sclerosis. <i>Expert Review of Neurotherapeutics</i> , 2019 , 19, 333-347	4.3	17
101	Endovascular treatment of CCSVI in patients with multiple sclerosis: clinical outcome of 462 cases. <i>Neurological Sciences</i> , 2013 , 34, 1633-7	3.5	17
100	Serum and CSF N-acetyl aspartate levels differ in multiple sclerosis and neuromyelitis optica. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2011 , 82, 1355-9	5.5	17
99	APOE-epsilon4 is not associated with cognitive impairment in relapsing-remitting multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2009 , 15, 1489-94	5	17
98	Italian studies on early-onset multiple sclerosis: the present and the future. <i>Neurological Sciences</i> , 2004 , 25 Suppl 4, S346-9	3.5	17
97	International Pediatric MS Study Group Global Members Symposium report. <i>Neurology</i> , 2016 , 87, S110-66.5		16
96	Breastfeeding and post-partum relapses in multiple sclerosis patients. <i>Multiple Sclerosis Journal</i> , 2019 , 25, 1211-1216	5	15
95	Thrombotic microangiopathy induced by interferon beta in patients with multiple sclerosis: three cases treated with eculizumab. <i>CKJ: Clinical Kidney Journal</i> , 2017 , 10, 625-631	4.5	15
94	Current recommendations for multiple sclerosis treatment in pregnancy and puerperium. <i>Expert Review of Clinical Immunology</i> , 2013 , 9, 683-91; quiz 692	5.1	15
93	Assessing executive function with the D-KEFS sorting test: normative data for a sample of the Italian adult population. <i>Neurological Sciences</i> , 2014 , 35, 1895-902	3.5	15
92	Natalizumab therapy of multiple sclerosis: recommendations of the Multiple Sclerosis Study Group--Italian Neurological Society. <i>Neurological Sciences</i> , 2011 , 32, 351-8	3.5	15
91	Interobserver agreement on PoserB and the new McDonaldB diagnostic criteria for multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2003 , 9, 481-5	5	15
90	Aggressive multiple sclerosis (1): Towards a definition of the phenotype. <i>Multiple Sclerosis Journal</i> , 2020 , 1352458520925369	5	14
89	Adverse events after endovascular treatment of chronic cerebro-spinal venous insufficiency (CCSVI) in patients with multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2013 , 19, 961-3	5	14
88	The pharmacovigilance program on natalizumab in Italy: 2 years of experience. <i>Neurological Sciences</i> , 2009 , 30 Suppl 2, S163-5	3.5	14
87	The influence of high dose intravenous immunoglobulins on immunological and metabolic pattern in newly diagnosed type I diabetic patients. <i>Journal of Autoimmunity</i> , 1990 , 3, 587-92	15.5	14
86	Study protocol: improving cognition in people with progressive multiple sclerosis: a multi-arm, randomized, blinded, sham-controlled trial of cognitive rehabilitation and aerobic exercise (COGEx). <i>BMC Neurology</i> , 2020 , 20, 204	3.1	14
85	Abnormal cerebellar functional MRI connectivity in patients with paediatric multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2016 , 22, 292-301	5	13

84	Cognitive rehabilitation in children and adolescents with multiple sclerosis. <i>Neurological Sciences</i> , 2010 , 31, S275-8	3.5	13
83	History of multiple sclerosis in 2 successive pregnancies: A French and Italian cohort. <i>Neurology</i> , 2016 , 87, 1360-7	6.5	13
82	Pronounced Structural and Functional Damage in Early Adult Pediatric-Onset Multiple Sclerosis with No or Minimal Clinical Disability. <i>Frontiers in Neurology</i> , 2017 , 8, 608	4.1	12
81	Donepezil for memory impairment in multiple sclerosis. <i>Lancet Neurology</i> , 2005 , 4, 72-3	24.1	12
80	MxA mRNA quantification and disability progression in interferon beta-treated multiple sclerosis patients. <i>PLoS ONE</i> , 2014 , 9, e94794	3.7	12
79	Illness perceptions and psychological adjustment among persons with multiple sclerosis: the mediating role of coping strategies and social support. <i>Disability and Rehabilitation</i> , 2020 , 42, 3780-3792 ^{2.4}		12
78	Cognitive impairment in multiple sclerosis: An exploratory analysis of environmental and lifestyle risk factors. <i>PLoS ONE</i> , 2019 , 14, e0222929	3.7	11
77	Cognitive impairment and event-related potentials in paediatric multiple sclerosis: 2-year study. <i>Neurological Sciences</i> , 2011 , 32, 1043-6	3.5	11
76	Changes in magnetic resonance imaging disease measures over 3 years in mildly disabled patients with relapsing-remitting multiple sclerosis receiving interferon β 1a in the COGNITIVE Impairment in Multiple Sclerosis (COGIMUS) study. <i>BMC Neurology</i> , 2011 , 11, 125	3.1	11
75	Switching to second-line therapies in interferon-beta-treated relapsing-remitting multiple sclerosis patients. <i>European Neurology</i> , 2009 , 61, 177-82	2.1	11
74	Pharmacoeconomic considerations of multiple sclerosis therapy with the new disease-modifying agents. <i>Expert Opinion on Pharmacotherapy</i> , 2004 , 5, 2115-26	4	11
73	Subcutaneous Interferon Beta-1a Has a Positive Effect on Cognitive Performance in Mildly Disabled Patients with Relapsing-Remitting Multiple Sclerosis: 2-Year Results from the COGIMUS Study. <i>Therapeutic Advances in Neurological Disorders</i> , 2009 , 2, 67-77	6.6	10
72	Effect of organizational features on patient satisfaction with care in Italian multiple sclerosis centres. <i>European Journal of Neurology</i> , 2017 , 24, 631-637	6	9
71	MRI substrates of sustained attention system and cognitive impairment in pediatric MS patients. <i>Neurology</i> , 2017 , 89, 1265-1273	6.5	9
70	Neopterin production and tryptophan degradation during 24-months therapy with interferon beta-1a in multiple sclerosis patients. <i>Journal of Translational Medicine</i> , 2011 , 9, 42	8.5	9
69	Natalizumab: a country-based surveillance program. <i>Neurological Sciences</i> , 2008 , 29 Suppl 2, S235-7	3.5	9
68	Clinical correlations of CSF single IgG bands. <i>Journal of Neurology</i> , 2005 , 252, 1274-5	5.5	9
67	The caring experience in multiple sclerosis: Caregiving tasks, coping strategies and psychological well-being. <i>Health and Social Care in the Community</i> , 2020 , 28, 236-246	2.6	9

66	Gray matter atrophy cannot be fully explained by white matter damage in patients with MS. <i>Multiple Sclerosis Journal</i> , 2021 , 27, 39-51	5	9
65	The Contribution of Illness Beliefs, Coping Strategies, and Social Support to Perceived Physical Health and Fatigue in Multiple Sclerosis. <i>Journal of Clinical Psychology in Medical Settings</i> , 2021 , 28, 149-160	160	9
64	Long-term disability trajectories in relapsing multiple sclerosis patients treated with early intensive or escalation treatment strategies. <i>Therapeutic Advances in Neurological Disorders</i> , 2021 , 14, 17562864211019574	66	9
63	The heritage of glatiramer acetate and its use in multiple sclerosis. <i>Multiple Sclerosis and Demyelinating Disorders</i> , 2016 , 1,	0	8
62	Emotional and neutral verbal memory impairment in Multiple Sclerosis. <i>Journal of the Neurological Sciences</i> , 2014 , 341, 28-31	3.2	8
61	Fluctuations of MS births and UV-light exposure. <i>Acta Neurologica Scandinavica</i> , 2013 , 127, 301-8	3.8	8
60	A steroid-induced bilateral avascular necrosis of the femoral head in an underage patient affected by multiple sclerosis. <i>Clinical Cases in Mineral and Bone Metabolism</i> , 2015 , 12, 257-9		8
59	ApolipoproteinE epsilon 4 allele is not associated with disease course and severity in multiple sclerosis. <i>Acta Neurologica Scandinavica</i> , 2009 , 120, 439-41	3.8	8
58	Delay from treatment start to full effect of immunotherapies for multiple sclerosis. <i>Brain</i> , 2020 , 143, 2742-2756	11.2	8
57	Natalizumab, Fingolimod and Dimethyl Fumarate Use and Pregnancy-Related Relapse and Disability in Women With Multiple Sclerosis. <i>Neurology</i> , 2021 ,	6.5	8
56	Longitudinal changes in social functioning in mildly disabled patients with relapsing-remitting multiple sclerosis receiving subcutaneous interferon β 1a: results from the COGIMUS (COGNitive Impairment in MULTiple Sclerosis) study (II). <i>Quality of Life Research</i> , 2012 , 21, 1111-21	3.7	7
55	A case of Takotsubo syndrome during a multiple sclerosis brainstem relapse. <i>Multiple Sclerosis and Related Disorders</i> , 2018 , 24, 1-2	4	7
54	Effects of 2-year treatment with dimethyl fumarate on cognition and functional impairment in patients with relapsing remitting multiple sclerosis. <i>Neurological Sciences</i> , 2020 , 41, 3185-3193	3.5	6
53	Aggressive multiple sclerosis (2): Treatment. <i>Multiple Sclerosis Journal</i> , 2020 , 1352458520924595	5	6
52	Disease modifying treatments and symptomatic drugs for cognitive impairment in multiple sclerosis: where do we stand?. <i>Multiple Sclerosis and Demyelinating Disorders</i> , 2017 , 2,	0	6
51	Injectable Versus Oral First-Line Disease-Modifying Therapies: Results from the Italian MS Register. <i>Neurotherapeutics</i> , 2021 , 18, 905-919	6.4	6
50	Multiple sclerosis in 2017: Progress in multiple sclerosis - from diagnosis to therapy. <i>Nature Reviews Neurology</i> , 2018 , 14, 72-74	15	5
49	The dilemma of benign multiple sclerosis: Can we predict the risk of losing the "benign status"? A 12-year follow-up study. <i>Multiple Sclerosis and Related Disorders</i> , 2018 , 26, 71-73	4	5

48	Multiple sclerosis in Latin America: A different disease course severity? A collaborative study from the MSBase Registry. <i>Multiple Sclerosis Journal - Experimental, Translational and Clinical</i> , 2015 , 1, 2055217315600193		
47	Is there a future for donepezil therapy in the treatment of multiple sclerosis-related cognitive impairment?. <i>Expert Review of Neurotherapeutics</i> , 2011 , 11, 1243-6	4.3	4
46	Gray matter atrophy correlates with MS disability progression measured with MSFC but not EDSS. <i>Journal of the Neurological Sciences</i> , 2009 , 284, 223; author reply 223-4	3.2	4
45	Longitudinal follow-up of "benign" multiple sclerosis at 20 years. <i>Neurology</i> , 2007 , 69, 938; author reply 938-9	6.5	4
44	Risk of Getting COVID-19 in People With Multiple Sclerosis: A Case-Control Study.. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2022 , 9,	9.1	4
43	Performance of the 2017 and 2010 Revised McDonald Criteria in Predicting MS Diagnosis After a Clinically Isolated Syndrome: A MAGNIMS Study. <i>Neurology</i> , 2021 ,	6.5	4
42	Disease-modifying therapy aids cognition in multiple sclerosis. <i>Nature Reviews Neurology</i> , 2020 , 16, 525-536	5.3	3
41	Immunohistochemistry analysis of bone marrow biopsies in multiple sclerosis patients undergoing autologous haematopoietic stem cells transplantation. <i>Clinical Neurology and Neurosurgery</i> , 2013 , 115, 1044-8	2	3
40	Maturation Trajectory of Processing Speed Performance in Pediatric Multiple Sclerosis. <i>Developmental Neuropsychology</i> , 2017 , 42, 299-308	1.8	3
39	The still under-investigated role of cognitive deficits in PML diagnosis. <i>Multiple Sclerosis and Demyelinating Disorders</i> , 2017 , 2,	0	3
38	Clinical case reviews in multiple sclerosis spasticity: experiences from around Europe. <i>Expert Review of Neurotherapeutics</i> , 2013 , 13, 61-6	4.3	3
37	Cognitive and psychosocial features of childhood and juvenile MS. <i>Neurology</i> , 2009 , 72, 1189; author reply 1189-90	6.5	3
36	Less Frequent and Less Severe Flu-Like Syndrome in Interferon Beta-1a Treated Multiple Sclerosis Patients with at Least One Allele Bearing the G>C Polymorphism at Position -174 of the IL-6 Promoter Gene. <i>PLoS ONE</i> , 2015 , 10, e0135441	3.7	3
35	The Use of Immunosuppressant Therapy for Multiple Sclerosis in Italy: A Multicenter Retrospective Study. <i>PLoS ONE</i> , 2016 , 11, e0157721	3.7	3
34	PML risk is the main factor driving the choice of discontinuing natalizumab in a large multiple sclerosis population: results from an Italian multicenter retrospective study. <i>Journal of Neurology</i> , 2021 , 1	5.5	3
33	Effects of High- and Low-Efficacy Therapy in Secondary Progressive Multiple Sclerosis. <i>Neurology</i> , 2021 , 97, e869-e880	6.5	3
32	Early Predictors of 9-Year Disability in Pediatric Multiple Sclerosis. <i>Annals of Neurology</i> , 2021 , 89, 1011-1022	10.2	3
31	The Brain-Derived Neurotrophic Factor Val66Met Polymorphism Can Protect Against Cognitive Impairment in Multiple Sclerosis. <i>Frontiers in Neurology</i> , 2021 , 12, 645220	4.1	3

30	A decline in cognitive function should lead to a change in disease-modifying therapy - Commentary. <i>Multiple Sclerosis Journal</i> , 2018 , 24, 1685-1686	5	2
29	Cognitive dysfunction in pediatric-onset multiple sclerosis134-143		2
28	Evidence for relative cortical sparing in benign multiple sclerosis: a longitudinal magnetic resonance imaging study. <i>Multiple Sclerosis Journal</i> , 2009 , 15, 403; author reply 404	5	2
27	Comparing natural history of early and late onset pediatric multiple sclerosis.. <i>Annals of Neurology</i> , 2022 ,	9.4	2
26	Tracking cognitive impairment in multiple sclerosis using the Brain on Track test: a validation study. <i>Neurological Sciences</i> , 2020 , 41, 183-191	3.5	2
25	Pregnancy in multiple sclerosis women with relapses in the year before conception increases the risk of long-term disability worsening. <i>Multiple Sclerosis Journal</i> , 2021 , 13524585211023365	5	2
24	The introduction of new medications in pediatric multiple sclerosis: Open issues and challenges. <i>Multiple Sclerosis Journal</i> , 2021 , 27, 479-482	5	2
23	Author response: Pregnancy decision-making in women with multiple sclerosis treated with natalizumab: I: Fetal risks. <i>Neurology</i> , 2018 , 91, 851	6.5	2
22	Current international trends in the treatment of multiple sclerosis in children-Impact of the COVID-19 pandemic. <i>Multiple Sclerosis and Related Disorders</i> , 2021 , 56, 103277	4	2
21	Early use of high-efficacy disease-modifying therapies makes the difference in people with multiple sclerosis: an expert opinion. <i>Journal of Neurology</i> ,	5.5	2
20	The diagnostic dilemma of multiple sclerosis presenting with isolated cognitive and behavioral disorders. <i>Multiple Sclerosis Journal</i> , 2017 , 23, 1561-1563	5	1
19	Retrospectively acquired cohort study to evaluate the long-term impact of two different treatment strategies on disability outcomes in patients with relapsing multiple sclerosis (RE.LO.DI.MS): data from the Italian MS Register. <i>Journal of Neurology</i> , 2019 , 266, 3098-3107	5.5	1
18	"Brain reserve" and "cognitive reserve" should always be taken into account when studying neurodegeneration - Commentary. <i>Multiple Sclerosis Journal</i> , 2018 , 24, 577-578	5	1
17	Confounders in natural history of interferon-beta-treated relapsing multiple sclerosis. <i>Annals of Neurology</i> , 2008 , 63, 126; author reply 126-7	9.4	1
16	Cognitive dysfunction in multiple sclerosis: current approaches to clinical management. <i>Expert Review of Neurotherapeutics</i> , 2002 , 2, 731-42	4.3	1
15	Cerebrospinal Fluid IgM and Oligoclonal IgG Bands in Multiple Sclerosis: A Meta-Analysis of Prevalence and Prognosis. <i>Brain Sciences</i> , 2021 , 11,	3.4	1
14	Mild gray matter atrophy in patients with long-standing multiple sclerosis and favorable clinical course. <i>Multiple Sclerosis Journal</i> , 2021 , 13524585211019650	5	1
13	Transition to secondary progression in relapsing-onset multiple sclerosis: Definitions and risk factors. <i>Multiple Sclerosis Journal</i> , 2021 , 27, 430-438	5	1

12	Defining the course of tumefactive multiple sclerosis: A large retrospective multicentre study. <i>European Journal of Neurology</i> , 2021 , 28, 1299-1307	6	1
11	Cognitive Issues in Pediatric Multiple Sclerosis. <i>Brain Sciences</i> , 2021 , 11,	3.4	1
10	Cardiorespiratory fitness and free-living physical activity are not associated with cognition in persons with progressive multiple sclerosis: Baseline analyses from the CogEx study. <i>Multiple Sclerosis Journal</i> , 2021 , 13524585211048397	5	1
9	The risk of infections for multiple sclerosis and neuromyelitis optica spectrum disorder disease-modifying treatments: Eighth European Committee for Treatment and Research in Multiple Sclerosis Focused Workshop Review. April 2021.. <i>Multiple Sclerosis Journal</i> , 2022 , 13524585211069068	5	1
8	Secondary Prevention in Radiologically Isolated Syndromes and Prodromal Stages of Multiple Sclerosis.. <i>Frontiers in Neurology</i> , 2022 , 13, 787160	4.1	1
7	Natalizumab treatment and pregnancy in multiple sclerosis: A reappraisal of maternal and infant outcomes after 6 years.. <i>Multiple Sclerosis Journal</i> , 2022 , 13524585221079598	5	1
6	The agenda of the global patient reported outcomes for multiple sclerosis (PROMS) initiative: Progresses and open questions.. <i>Multiple Sclerosis and Related Disorders</i> , 2022 , 61, 103757	4	0
5	Long-term Cognitive Outcomes and Socioprofessional Attainment in People With Multiple Sclerosis With Childhood Onset.. <i>Neurology</i> , 2022 , 98, e1626-e1636	6.5	0
4	The relationship between processing speed and verbal and non-verbal new learning and memory in progressive multiple sclerosis.. <i>Multiple Sclerosis Journal</i> , 2022 , 13524585221088190	5	0
3	Cognitive and Psychiatric Disorders in Multiple Sclerosis. <i>Blue Books of Neurology</i> , 2010 , 147-158		
2	Etiological research in pediatric multiple sclerosis: A tool to assess environmental exposures (PEDiatric Italian Genetic and enviRonment ExposurE Questionnaire). <i>Multiple Sclerosis Journal - Experimental, Translational and Clinical</i> , 2021 , 7, 20552173211059048	2	
1	A method to compare prospective and historical cohorts to evaluate drug effects. Application to the analysis of early treatment effectiveness of intramuscular interferon- β in multiple sclerosis patients. <i>Multiple Sclerosis and Related Disorders</i> , 2020 , 40, 101952	4	